ABOUT PRODUCTS INVESTORS NEWS & EVENTS CAREERS PRESS RELEASES 10/7/14 U.S. FDA Accepts IDE Submission by Cerus Making the INTERCEPT Blood System Available to Address Chikungunya and Dengue Blood Safety Risks 9/11/14 Cerus and Biomedica Foscama Group S.p.A. Enter Distribution Agreement for the INTERCEPT Blood System in Italy 9/10/14 Cerus Submits IDE Supplement to Make INTERCEPT Platelets Available Pre-Approval in U.S. Areas at Risk from Outbreaks of Chikungunya and Dengue ABOUT CERUS Cerus Corporation is a biomedical products company focused in the field of blood safety. Cerus currently markets and sells the INTERCEPT Blood System for both platelets and plasma in Europe, the Commonwealth of Independent States, the Middle East and selected countries in other regions around the world. In the United States, Cerus is seeking regulatory approval of the INTERCEPT Blood System for plasma and platelets. The INTERCEPT red blood cell system is in clinical development. ANNUAL REPORT Cerus' Annual Meeting of Stockholders was held on Wednesday, June 11, 2014 at 9:00am PDT. <more information> 2013 Annual Report About CERUS Mission & Values Investor Overview News & Events Careers Site Map GLOBAL HEADQUARTERS 2550 Stanwell Drive Concord, CA US 94520 +1 925.288.6000 EUROPEAN HEADQUARTERS Stationsstraat 79-D 3811 MH Amersfoort, Netherlands +31 (0) 33 49 60 600 EMAIL ALERTS Alerts are emailed to you when certain new company information is posted to this site. > Sign up now! The INTERCEPT Blood System is not approved for sale in the US and certain other countries. Copyright @ 2014 Cerus Corporation Privacy Legal Site Map Powered By Q4 Web Systems 4.0.6.245